REVBNasdaqPharmaceutical PreparationsFiscal year ends December 31Also trades as REVBW
REVELATION BIOSCIENCES, INC.
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Aug 6, 2026
$3.29+2.80 (+577.76%)
Close on Oct 19, 2026
- Market cap
- $12.58M
- P/E (TTM)
- –
- Dividend yield
- –
Share price
−$1.87 (−36.34%)past year
Daily closes, adjusted for splits. Drag across the chart to measure a change.EarningsSplit
Key statistics
Valuation at the latest close; fundamentals over fiscal , balances at Jun 30, 2026
Valuation
- Market cap
- $12.58M
- P/E ratio
- –
- Price to sales
- –
- Price to book
- 1.25
- Dividend yield
- –
- Free cash flow yield
- –
Fundamentals
- Net income
- -$10.75M
- EPS, diluted
- -$23.95
- Book value per share
- $2.63
- Diluted shares
- 4M
Seven years at a glance
Fiscal years 2019 to 2025 and trailing twelve months, USD
Operating income
-$11.27M
Net income
-$10.75M
EPS, diluted
–
Free cash flow
–
Reported periodTrailing twelve months